NeoVirTech (NVT) and BioImmunitas Ltd enter a long-term partnership to advance a human recombinant protein therapeutic platform from bench to bedside. BioImmunitas Ltd has developed a highly cost-efficient series of recombinant proteins which form the platform therapeutic agent. This highly innovative treatment has been shown to be efficacious in several different therapeutic areas. Their collaboration with NeoVirTech has seen BioImmunitas utilize NVT’s proprietary antiviral discovery platform to position its own therapeutic hRPP on the anti-viral market.